SCHEMBL10010147

SCHEMBL10010147

Cc1cc(-n2nc(Nc3ccc(F)c(F)c3)cc2C)ccn1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KCNN3 Q9UGI6 1/20 0.43
▸ GSK3B P49841 3/20 0.39
▸ TDO2 P48775 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAPGEF4 Q8WZA2 1/20 0.38
▸ DHFR P00374 1/20 0.38
▸ KCNJ6 P48051 2/20 0.37
▸ KCNJ5 P48544 2/20 0.37
▸ KCNJ3 P48549 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ MAPK1 P28482 3/20 0.37
▸ TP53 P04637 1/20 0.35
▸ EIF2AK2 P19525 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506198 0.84 MAPK1 (0.38) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL1506106 0.83 MAPK1 (0.36) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL1506344 0.82 MAPK1 (0.36) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL1506338 0.82 JAK2 (0.37) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL1506262 0.81 KCNJ6 (0.41) GSK3BKCNJ6KCNJ5KCNJ3MAPK1
SCHEMBL10008635 0.80 MAPK1 (0.35) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL1506218 0.80 KCNJ6 (0.40) GSK3BKCNJ6KCNJ5KCNJ3MAPK1
SCHEMBL27982244 0.80 MAPK1 (0.35) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL10009314 0.80 MAPK1 (0.35) KCNN3GSK3BTDO2KDM4EMAPT
SCHEMBL1506151 0.79 P2RX7 (0.39) KCNJ6KCNJ5KCNJ3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 KCNN3 414/4885GSK3B 1943/4885TDO2 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback